Fanni Santa, MD @FV_Santa

As another academic year winds down, I just want to acknowledge the amazing GU pathology team at BWH, especially our graduating fellows @_RamyaPrabhu and Ceasr Torres Gutierrez. 🎓Thank you for all of your hard work! You are ready!!🔬 #proud #GUpathrocks @BWHPath @MGBpathology

Congrats to the whole team @DanaFarber_GU on this new @AACR paper in Molecular Cancer Research This is the result of over 4+ years of work with 3 labs @DanaFarber, where @adib_elio @AminNassarMD @sarahaboualaiwi were residents/fellows @BrighamMedRes @YaleCancer and @SylvanBacaLab was a post-doc! Thank you @MichelleDunno17 @SashaGusevPosts @mouwlab for being the best collaborators! Link: aacrjournals.org/mcr/article/do…

keyboard_arrow_left Previous keyboard_arrow_right Next

Here’s our latest, we explored tumor B-cell infiltration in advanced urothelial carcinoma. Exciting collaboration with @OncoBellmunt Congrats to leading authors @KonradStawiski @PereraBel #BladderCancer #Bcells #TLS #MIBC

Now in press in Virchows Archiv-->Multi-institutional cohort of 18 renal tumors, uniquely ALL with proven FLCN biallelic inactivation -> morphology, molecular, IHC, and clinical follow-up.🔬 @ESP_Pathology @GU_Path_Society @IntSocUropath #kidneycancer #BHD #birthoggdube #gupath

Applications are now open for the AACR-Exelixis Renal Cell Carcinoma Research Fellowship! This two-year, $130,000 fellowship supports postdoctoral or clinical research fellows conducting renal cell carcinoma research across basic, translational, clinical, or population sciences. Deadline: June 11 Learn more and apply: bit.ly/AACR-Exelixis #AcceleratingCures

Just published in the May 2027 issue of The American Journal of Surgical Pathology @JLHornick, in  memory of our dear friend, mentor, and exceptional educator and leader, Dr. Sambit Mohanty.   In the largest series to date of ALK-rearranged renal cell carcinoma (ALK-RCC), Drs. Anandi Lobo @LoboAnandi, Mahmut Akgul, Ankur Sangoi @slusagar, Khaleel Al-Obaidy,@KhaleelAlObaidy @Andres_M_Acosta @Aparwani_dpath @DrSeemaKaushal @Williamson_SR and their distinguished colleagues present an integrated clinicopathologic, morphologic, and molecular analysis of this rare aggressive tumor (PMID: 41790060).   ALK-RCC in adults demonstrates significant morphologic heterogeneity and carries important clinical implications. Accurate diagnosis is critical, as patients - particularly those with metastatic disease- may benefit from ALK-targeted therapies. Notably, TFE3 immunoreactivity can be seen in ALK-RCC, making confirmation of ALK gene rearrangement essential through immunohistochemistry and/or molecular methods such as FISH or NGS.   Given its diverse morphology, ALK-RCC can mimic other renal neoplasms, including TFE3-rearranged RCC, clear cell papillary renal cell tumor, and mucinous tubular and spindle cell carcinoma, posing a risk for misclassification. Recognition of key features- such as solid and tubulopapillary architecture, eosinophilic cytology, and ALK/KRT7 expression - combined with confirmatory molecular testing is crucial, especially in younger patients or diagnostically challenging cases.   This study expands our understanding of ALK-RCC, underscoring its rarity, diagnostic complexity, and variable clinical behavior. Accurate diagnosis, facilitated by molecular diagnostics, is essential not only to avoid misdiagnosis but also to identify patients who may benefit from targeted therapy.   Take a look: journals.lww.com/ajsp/fulltext/…

keyboard_arrow_left Previous keyboard_arrow_right Next

Free access: onlinelibrary.wiley.com/doi/10.1002/il… I am absolutely delighted to share this state-of-the-art review on “Evolving Landscape of Precision Medicine in Bladder Cancer: From Challenges to Clinical Impact.”, written by Prof. Ting Ye and colleagues – one of most comprehensive and up-to-date review on bladder cancer care. Bladder cancer (BCa) remains one of the most challenging urologic malignancies due to its marked molecular heterogeneity, high recurrence rates, and variable therapeutic responses. However, the rapid emergence of precision oncology is transforming the field and opening unprecedented opportunities for personalized treatment strategies. In this review, we provide an updated synthesis of recent advances in the molecular characterization, diagnostic innovations, and targeted therapeutic strategies for BCa. We discuss the evolving molecular landscape, highlighting recurrent genomic alterations - including FGFR3, TP53, RB1, ERBB2, and PIK3CA - and their differential prevalence in non–muscle-invasive versus muscle-invasive disease. Advances in molecular subtyping using transcriptomic and epigenetic profiling have further refined prognostic and predictive stratification. We also examine the critical role of the tumor microenvironment, including immune cell infiltration, stromal remodeling, and angiogenic programs, in shaping therapeutic response and guiding treatment strategies. On the therapeutic front, we highlight precision approaches involving FGFR inhibitors, HER2-targeted agents, PI3K/AKT/mTOR pathway inhibitors, immune checkpoint blockade, antibody-drug conjugates, and emerging modalities such as RNA therapeutics and oncolytic platforms. Despite these advances, important challenges remain, including intratumoral heterogeneity, clonal evolution, resistance mechanisms, and disparities in access to genomic testing. Emerging technologies - including multi-omics integration, spatial transcriptomics, single-cell profiling, artificial intelligence–driven predictive modeling, and liquid biopsy monitoring - hold great promise for overcoming these barriers and improving clinical decision-making. Looking ahead, the future of precision medicine in BCa will rely on the integration of comprehensive multi-omics datasets, AI-enabled predictive analytics, and minimally invasive monitoring strategies such as circulating tumor DNA (ctDNA) and exosomal RNA profiling. Novel immunotherapeutic strategies - including bispecific antibodies, neoantigen vaccines, CAR-T therapies, and TCR-engineered cells - may further expand treatment options, particularly for patients with checkpoint inhibitor - refractory disease. Ultimately, the convergence of high-throughput molecular profiling, advanced computational analytics, and real-time tumor monitoring is shifting BCa management from a reactive, one-size-fits-all paradigm toward proactive, adaptive, and highly personalized cancer care.

keyboard_arrow_left Previous keyboard_arrow_right Next

Do you have an interesting #gupath case that you want to share with the global community through the @IntSocUropath as the Case of the Month? All #ISUP members are invited to submit to [email protected] using the available template, we would love to include it in 2026!

The GUPS and ISUP Joint Expert Consultation Recommendations on intraductal carcinoma of the prostate - Shah - 2026 - Histopathology - Wiley Online Library #gupath #openaccess onlinelibrary.wiley.com/doi/10.1111/hi…

Rethinking Gleason pattern quantification in predicting metastasis: results of 20 years of follow‐up in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer - Kroon - Histopathology - Wiley Online Library #gupath onlinelibrary.wiley.com/doi/10.1111/hi…

GPNMB immunohistochemistry is a useful ancillary tool for the diagnosis of pulmonary lymphangioleiomyomatosis - Szalai - Histopathology - Wiley Online Library #lungpath #openaccess onlinelibrary.wiley.com/doi/10.1111/hi…

Special Nov edition on #Gupath onlinelibrary.wiley.com/toc/13652559/c…

Enjoy Kidney Cancer's Special Pathology Edition. A great set of [open access] RCC reviews; also, sarcomas, benign tumors, molecular changes, familial syndromes, grading/staging. Great for patients, clinicians, researchers & pathologists.🔬#gupath @urotoday journals.sagepub.com/toc/kcaa/9/1_s…

Mass General Brigham (MGB) Pathology is now accepting applications for our 2027-2028 combined BWH/MGH GU Pathology Fellowship. If you love GU pathology 🔬 and Boston 🦞, consider applying @ [email protected] #gupath #gupathrocks @MGBpathology

I am profoundly honored to assume the role of President of the International Society of Urologic Pathology (ISUP) @IntSocUropath this week. It is a privilege to serve this esteemed community and work alongside colleagues dedicated to advancing the field of Urologic Surgical Pathology. I look forward to collaborating with all of you to drive innovation, education, and excellence in our specialty. These are exciting times for our field, and together, we will continue to shape the future of urologic pathology!

@BKA_MD @BIDMCpath @harvardmed Congratulations!! 🎉

I'm incredibly grateful to have worked under the guidance of the most wonderful mentors, Dr. Cheng and Dr. Akgul. Their expertise and mentorship made this collaboration not just successful but truly inspiring. It was the greatest pleasure to work on this project! #pathology #GU

Liang Cheng, MD @LiangChengMD

a year ago

I’m happy to share our latest review article, "Primary Adenocarcinoma of the Urinary Tract and Its Precursors: Diagnostic Criteria and Classification," just published @Human_Pathology. Drs. Santa, Akgul, and colleagues provide a comprehensive review of the diagnosis,

keyboard_arrow_left Previous keyboard_arrow_right Next

0 19 52 4K 19

@MichelleDunno17 @Andres_M_Acosta @BWHPath @BWHUrology @DanaFarber_GU @GU_Path_Society @IntSocUropath Congratulations!! 🎉

Happy International Pathology Day to all pathologist, scientists, laboratory assistants, medical students and pathology enthusiasts! Great to be part of this community! #pathX #pathology #pathX #histology #MedTwitter

@StainsFile Thank you!!

I’m immensely grateful to have reached this milestone: becoming a doctor 🙏🏻👩‍⚕️ But while one chapter ends, another has just begun. On my way to create The Path, becoming a pathologist and researcher 🔬 #Path2Path #PathX #PathTwitter #medicalstudent #usmle #GUPath #Science